natgillin/translations-raw huggingface dataset:
- if you have kidney problems (severely impaired renal function) and/or liver problems (severely impaired hepatic function), do not take Ketek while taking other medicines containing any of the following active substances:
- ako imate probleme s bubrezima (teško oštećenje funkcije bubrega) i/ili probleme s jetrom (teško oštećenje funkcije jetre), nemojte uzimati Ketek dok uzimate druge lijekove koji sadrže neku od sljedećih djelatnih tvari:
Ventricular arrhythmias (including ventricular tachycardia, torsade de pointes) have been reported in patients treated with telithromycin and sometimes occurred within a few hours of the first dose (see
Ventrikularne artimije (uključujući ventrikularnu tahikardiju, torsades de pointes) prijavljene su u bolesnika liječenih telitromicinom i ponekad su se pojavile unutar nekoliko sati od prve doze (vidjeti
Concomitant treatment with these medicinal products is likely to result in subtherapeutic levels of telithromycin and therefore encompass a risk of treatment failure (see section 4.5).
Istodobna primjena tih lijekova vjerojatno će rezultirati supterapijskim koncentracijama telitromicina te stoga nosi rizik od neuspjeha liječenja (vidjeti dio 4.5).
Studies in rats and rabbits were inconclusive with respect to potential for teratogenicity; there was equivocal evidence of adverse effects on foetal development at high doses.
Istraživanja na štakorima i kunićima nisu pružila nedvojben odgovor o mogućoj teratogenosti, a dokazi o štetnim učincima na razvoj fetusa pri visokim dozama
Interaction studies with itraconazole and ketoconazole, two CYP3A4 inhibitors, showed that maximum plasma concentrations of telithromycin were increased respectively by 1.22 and 1.51 fold and AUC by respectively 1.54 fold and 2.0 fold.
Ispitivanja interakcija s itrakonazolom i ketokonazolom, dvama inhibitorima CYP3A4, pokazala su da su kod istodobne primjene maksimalne koncentracije telitromicina u plazmi porasle 1,22 odnosno 1,51 puta, a njegov AUC 1,54 odnosno 2,0 puta.
The effect of dialysis on the elimination of telithromycin has not been assessed.
Učinak dijalize na eliminaciju telitromicina još nije ocijenjen.
Ketek is not recommended as first choice in patients with severe renal impairment (creatinine clearance <30 ml/min) or patients with both severe renal impairment and co-existing hepatic impairment, as an optimal dosage format (600 mg) is not available.
Ketek se ne preporučuje kao prvi izbor u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) niti u bolesnika koji imaju teško oštećenje bubrega i istodobno oštećenje jetre jer ne postoji prikladan oblik doziranja lijeka (600 mg).
The pharmacokinetics of telithromycin is similar between males and females.
-Spol Farmakokinetika telitromicina podjednaka je u muškaraca i žena.
Exposure to telithromycin in vitro did select for pneumococcal mutants with increased MICs of telithromycin, generally resulting in MIC values of ≤1 mg/l.
S izloženošću telitromicinu in vitro izdvojili su se pneumokokni mutanti s povećanim MIK-ovima telitromicina, što je u pravilu rezultiralo vrijednostima MIK-a od ≤ 1 mg/l.
Ketek is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4.
Ketek je inhibitor CYP3A4 i samo se u posebnim okolnostima smije primjenjivati tijekom liječenja drugim lijekovima koji se metaboliziraju putem CYP3A4.
There were no reports of TdP or other serious ventricular arrhythmias or related syncope in the clinical program and no subgroups at risk were identified.
U kliničkom programu nisu prijavljeni torsade de pointes niti druge ozbiljne ventrikularne aritmije ili povezani slučajevi sinkope, a nisu utvrđene ni rizične podskupine.
Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.
Bolesnicima treba savjetovati da prekinu liječenje i obrate se liječniku ako se razviju znakovi i simptomi jetrene bolesti, kao što su anoreksija, žutica, tamna mokraća, svrbež ili osjetljivost
Hence, telithromycin should be used with caution (see also sections 4.4 and 5.2).
Stoga telitromicin u tih bolesnika treba primjenjivati uz oprez (vidjeti također dio 4.4 i 5.2).
• ketoconazole or fluconazole (anti-fungal treatment)
• ketokonazol ili flukonazol (za liječenje gljivičnih infekcija)
If telithromycin treatment is deemed necessary, these patients may be treated with alternating daily doses of 800 mg and 400 mg, starting with the 800 mg
Ako se liječenje telitromicinom smatra neophodnim, takve se bolesnike može liječiti naizmjeničnim davanjem dnevnih doza od 800 mg i 400 mg, počevši s dozom
>0.5 mg/l
> 0,5 mg/l > 0,5 mg/l > 8 mg/l > 0,5 mg/l
If pseudomembranous colitis is suspected, the treatment must be stopped immediately and patients should be treated with supportive measures
Posumnja li se na pseudomembranski kolitis, liječenje se mora odmah prekinuti, a bolesnika liječiti potpornom i/ili specifičnom terapijom.
In in vitro studies the activity of telithromycin was reduced against organisms that express the erythromycin erm(B) or mef(A) related resistance mechanisms.
U ispitivanjima in vitro aktivnost telitromicina bila je smanjena protiv organizama koji iskazuju mehanizme rezistencije na eritromicin povezane s ekspresijom gena erm(B) ili mef(A).
Furthermore, telithromycin is able to block the formation of the
Osim toga, telitromicin može blokirati stvaranje ribosomskih podjedinica
The induction gradually decreases during 2 weeks after cessation of treatment with CYP3A4 inducers.
Indukcija se postupno smanjuje tijekom 2 tjedna nakon prestanka liječenja induktorima CYP3A4.
Ergot alkaloid derivatives (such as ergotamine and dihydroergotamine) By extrapolation from erythromycin A and josamycin, concomitant medication of Ketek and alkaloid derivatives could lead to severe vasoconstriction (“ergotism”) with possibly necrosis of the extremities.
Derivati ergot alkaloida (poput ergotamina i dihidroergotamina) Sudeći prema iskustvu s eritromicinom A i josamicinom, istodobna primjena lijeka Ketek i derivata alkaloida može dovesti do teške vazokonstrikcije ("ergotizma") s mogućom nekrozom udova.
• saquinavir (anti-HIV treatment) - if you are taking other medicines containing any of the following active substances:
• sakvinavir (za liječenje HIV infekcije) - ako uzimate druge lijekove koji sadrže neku od sljedećih djelatnih tvari:
Strong CYP3A4 inhibitors must not be co-administered with Ketek in patients with severe renal/or hepatic dysfunction (see section 4.3).
Snažni inhibitori CYP3A4 ne smiju se primjenjivati zajedno s lijekom Ketek u bolesnika s teškim oštećenjem bubrežne ili jetrene funkcije (vidjeti dio 4.3).
Phospholipidosis (intracellular phospholipid accumulation) affecting a number of organs and tissues (e.g., liver, kidney, lung, thymus, spleen, gall bladder, mesenteric lymph nodes, GI-tract) has been observed in rats and dogs administered telithromycin at repeated doses of 150 mg/kg/day or more for 1 month and 20 mg/kg/day or more for 3-6 months.
Fosfolipidoza (intracelularna akumulacija fosfolipida) koja zahvaća brojne organe i tkiva (npr. jetru, bubrege, pluća, timus, slezenu, žučni mjehur, mezenterijske limfne čvorove, probavni sustav) zabilježena je u štakora i pasa koji su primali telitromicin u višekratnim dozama od 150 mg/kg na dan ili više tijekom mjesec dana, odnosno 20 mg/kg na dan tijekom 3-6 mjeseci.
In some organisms that are resistant to erythromycin A due to inducible expression of the MLSB resistance determinant, the affinity of telithromycin for the 50S ribosomal subunit is more than 20
U nekim organizmima koji su rezistentni na eritromicin A zbog inducibilne ekspresije odrednice rezistencije tipa MLSB, afinitet telitromicina za ribosomsku podjedinicu 50S je više od 20 puta veći od afiniteta eritromicina A.
Telithromycin has been shown to decrease the Cmax by 34 % and AUC of sotalol by 20 % due to
Pokazalo se da telitromicin smanjuje Cmax sotalola za 34% i bioraspoloživost (AUC) za 20% zbog
Telithromycin is an inhibitor of CYP3A4 and a weak inhibitor of CYP2D6.
Telitromicin je inhibitor CYP3A4 i slab inhibitor CYP2D6.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.
- The other ingredients are microcrystalline cellulose, povidone (K25), croscarmellose sodium, magnesium stearate in the tablet core as well as talc, macrogol (8000 ), hypromellose (6 cp), titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) in the film-coating.
- Drugi sastojci su mikrokristalična celuloza, povidon (K25), umrežena karmelozanatrij i magnezijev stearat u jezgri tablete te talk, makrogol (8000), hipromeloza (6cp), titanijev dioksid (E171), žuti željezov oksid (E172) i crveni željezov oksid (E172) u film ovojnici.
When midazolam was coadministered with Ketek, midazolam AUC was increased 2.2-fold after intravenous administration of midazolam and 6.1-fold after oral administration.
Kad se midazolam davao istodobno s lijekom Ketek, AUC midazolama povećao se 2,2 puta nakon intravenske, a 6,1 puta nakon peroralne primjene midazolama.
Patients with concomitant treatment of pravastatin, rosuvastatin or fluvastatin should be carefully monitored for signs and symptoms of myopathy and rhabdomyolysis.
Bolesnike koji istodobno uzimaju pravastatin, rosuvastatin ili fluvastatin treba pomno nadzirati zbog mogućih pojava znakova i simptoma miopatije i rabdomiolize.
Ketek 400 mg tablets are light orange, oblong, biconvex, film-coated tablets imprinted with “H3647” on one side and “400” on the other.
Ketek 400 mg tablete su svijetlonarančaste, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom "H3647" na jednoj i "400" na drugoj strani.
During concomitant administration of rifampicin and telithromycin in repeated doses, Cmax and AUC of telithromycin were on average decreased by 79% and 86% respectively.
Tijekom istodobne primjene rifampicina i telitromicina u ponovljenim dozama, Cmax telitromicina snižen je za prosječno 79%, a AUC za prosječno 86%.
Treatment with these agents should be interrupted during Ketek treatment.
Primjena ovih lijekova mora se privremeno prekinuti tijekom liječenja lijekom Ketek.
There is no clinically relevant pharmacokinetic interaction of Ketek and theophylline administered as extended release formulation.
Nema klinički značajne farmakokinetičke interakcije lijeka Ketek i teofilina primijenjenog u obliku s produljenim oslobađanjem.
No carcinogenicity studies have been conducted with telithromycin.
Nisu provedena ispitivanja kancerogenosti telitromicina.
The rate and extent of absorption is unaffected by food intake, and thus Ketek tablets can be given without regard to food.
Unos hrane ne utječe na brzinu i opseg apsorpcije pa se Ketek tablete mogu davati neovisno o obroku.
Streptococcus pneumoniae does not demonstrate cross-resistance between erythromycin A and
Streptococcus pneumoniae ne pokazuje križnu rezistenciju između eritromicina A i telitromicina.
Telithromycin is also a P-glycoprotein inhibitor.
Telitromicin je i inhibitor P-glikoproteina.
The recommended European Committee for Antimicrobial Susceptibility Testing (EUCAST) MIC clinical breakpoints are presented below:
Europski odbor za ispitivanje osjetljivosti na antibiotike (EUCAST) preporučio je sljedeće granične vrijednosti MIK-a u kliničkoj primjeni:
Concomitant administration of Ketek with drugs that are substrates of P-glycoprotein might result in increased exposure to the P-glycoprotein substrates such as digoxin and dabigatran etexilate.
Istodobna primjena lijeka Ketek s lijekovima koji su supstrati za P-glikoprotein mogla bi dovesti do povećane izloženosti supstratima P-glikoproteina, poput digoksina i dabigatraneteksilata.
Hence, Ketek should not be used during treatment with medicinal products that are CYP3A4 substrates, unless plasma concentrations of the CYP3A4 substrate, efficacy or adverse reactions can be closely monitored.
Stoga se Ketek ne smije davati tijekom primjene lijekova koji su supstrati CYP3A4, osim ako se mogu pomno nadzirati koncentracije supstrata CYP3A4 u plazmi, djelotvornost ili nuspojave lijeka.
• ergotamine or dihydroergotamine (tablets or inhaler for migraine) - if you have kidney problems (severely impaired renal function) and/or liver problems (severely impaired hepatic function), other medicines containing any of the following active substances:
• ergotamin ili dihidroergotamin (tablete ili inhalator za liječenje migrene) - ako imate tegoba s bubrezima (teško oštećenje bubrežne funkcije) i/ili tegoba s jetrom (teško oštećenje jetrene funkcije), drugi lijekovi koji sadrže neku od sljedećih djelatnih tvari:
If you feel you are suffering from a side effect, tell a doctor immediately to get advice before taking
Ako smatrate da imate neku nuspojavu, odmah o tome obavijestite liječnika kako bi Vam dao savjet prije uzimanja sljedeće doze.
Following oral administration, telithromycin is fairly rapidly absorbed.
Nakon peroralne primjene telitromicin se razmjerno brzo apsorbira.
It is important that patients prescribed telithromycin should be informed that visual adverse reactions may occur during the treatment (see sections 4.7 and
Važno je da bolesnici kojima je propisan telitromicin budu informirani kako se vizualne nuspojave mogu pojaviti tijekom liječenja (vidjeti dio 4.7 i 4.8).
Ketek should therefore not be used concomitantly with simvastatin, atorvastatin, or lovastatin (see section 4.3).
Ketek se stoga ne smije primjenjivati istodobno sa simvastatinom, atorvastatinom ili lovastatinom (vidjeti dio 4.3).
Aventis Pharma S.A. 20, Avenue Raymond Aron F-92160 ANTONY France
20, Avenue Raymond Aron F-92160 ANTONY Francuska
- if you are allergic to telithromycin, to any of the macrolide antibiotics or to any of the other ingredients of this medicine (listed in section 6).
- ako ste alergični na telitromicin, neki makrolidni antibiotik ili neki drugi sastojak ovog lijeka
Species for which acquired resistance may be a problem Staphylococcus aureus methicillin resistant (MRSA)+
Vrste kod kojih stečena rezistencija može predstavljati Aerobne gram-pozitivne bakterije Staphylococcus aureus rezistentan na meticilin (MRSA)+
When simvastatin was coadministered with Ketek, there was a 5.3-fold increase in simvastatin Cmax, an 8.9-fold increase in simvastatin AUC, a 15-fold increase in simvastatin acid Cmax and an 11-fold increase in simvastatin acid AUC.
Kada se simvastatin primjenjivao istodobno s lijekom Ketek, Cmax simvastatina povećao se 5,3 puta, a njegov AUC 8,9 puta, dok se Cmax simvastatinske kiseline povećao 15 puta, a AUC 11 puta.
There have been post-marketing adverse reaction reports of transient loss of consciousness including some cases associated with vagal syndrome (see sections 4.7 and 4.8).
U izvješćima o nuspojavama nakon stavljanja lijeka u promet prijavljeni su slučajevi prolaznog gubitka svijesti, uključujući neke slučajeve povezane s vagusnim sindromom (vidjeti dio 4.7 i 4.8).
In a single-dose study (800 mg) in 12 patients and a multiple-dose study (800 mg) in 13 patients with mild to severe hepatic insufficiency (Child Pugh Class A, B and C), the Cmax, AUC and t1/2 of telithromycin were similar compared to those obtained in age- and sex-matched healthy subjects.
U ispitivanju s primjenom jedne doze (800 mg) u 12 bolesnika i u ispitivanju s primjenom višekratnih doza (800 mg) u 13 bolesnika s blagim do teškim oštećenjem jetre (Child Pugh stadij A, B i C), Cmax, AUC i t1/2 telitromicina bili su slični onima u zdravih osoba iste dobi i spola.
Treatment with these agents should be interrupted during Ketek treatment (see section 4.5).
Primjenu ovih lijekova potrebno je privremeno prekinuti tijekom liječenja lijekom Ketek (vidjeti dio 4.5).
Concomitant administration of Ketek and any of these medicinal products is contraindicated (see section 4.3).
Kontraindicirana je istodobna primjena lijeka Ketek i bilo kojeg od tih lijekova (vidjeti dio 4.3).
If possible take the tablets before going to bed, to reduce the potential impact of visual disturbances and loss of consciousness.
Po mogućnosti uzimajte tablete prije odlaska na počinak kako bi se smanjio mogući utjecaj poremećaja vida i gubitka svijesti.
A mean maximum plasma concentration of about 2 mg/l is reached within 1-3 hour after dose with once-daily dosing of telithromycin 800 mg.
Prosječna maksimalna koncentracija u plazmi od oko 2 mg/l postiže se 1-3 sata nakon primjene doze od 800 mg telitromicina jedanput na dan.
- Community-acquired pneumonia: 800 mg once a day for 7 to 10 days, - Acute exacerbation of chronic bronchitis: 800 mg once a day for 5 days, - Acute sinusitis: 800 mg once a day for 5 days, - Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
U bolesnika u dobi od 18 ili više godina režim liječenja će, sukladno indikaciji, biti: - izvanbolnički stečena pneumonija: 800 mg jedanput na dan tijekom 7 do 10 dana, - akutna egzacerbacija kroničnog bronhitisa: 800 mg jedanput na dan tijekom 5 dana, - akutni sinusitis: 800 mg jedanput na dan tijekom 5 dana, - tonzilitis/faringitis uzrokovan bakterijom Streptococcus pyogenes: 800 mg jedanput na dan tijekom 5 dana.
Talk to your doctor, pharmacist or nurse before taking Ketek: - if you have had certain heart problems such as coronary heart disease, ventricular arrhythmias, bradycardia (changes in heart rate or electrocardiogram) or if you have had certain abnormal blood tests due to medical conditions such as low levels of potassium (hypokalaemia), low levels
Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Ketek: - ako ste imali određene srčane tegobe kao što su koronarna bolest srca, ventrikularne aritmije, bradikardija (promjene srčanog ritma ili elektrokardiograma) ili ako ste ste imali neke poremećaje u rezultatima krvnih pretraga uzrokovanih medicinskim stanjima kao što su niska razina kalija (hipokalijemija) ili niska razina magnezija (hipomagnezijemija).
Ketek has been shown to increase the plasma concentrations of digoxin, a P-glycoprotein substrate.
Pokazalo se da Ketek povisuje koncentracije digoksina, supstrata P-glikoproteina, u plazmi.
Based on simulation data, an alternating daily dosing regimen of 800 mg and 400 mg in patients with severe renal impairment can approximate the AUC (0-48h) in healthy subjects receiving 800 mg once daily.
Na temelju podataka dobivenih simulacijom, režimom naizmjenične primjene dnevnih doza od 800 mg i 400 mg u bolesnika s teškim oštećenjem bubrežne funkcije može se postići AUC(0-48h) približno jednak onome u zdravih ispitanika koji primaju dozu od 800 mg
• colchicine (for gout).
• kolhicin (za liječenje gihta).
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Kada je lokalna prevalencija rezistencije takva da je korist lijeka barem u nekim vrstama infekcija upitna, po potrebi treba potražiti savjet stručnjaka.
There is no pharmacodynamic or clinically relevant pharmacokinetic interaction with low-dose triphasic oral contraceptives in healthy subjects.
U zdravih ispitanika nema farmakodinamičkih niti klinički značajnih farmakokinetičkih interakcija s trofaznim oralnim kontraceptivima s niskim dozama hormona.
In areas with a high incidence of erythromycin A resistance, it is especially important to take into consideration the evolution of the pattern of susceptibility to telithromycin and other antibiotics.
A posebno je važno uzeti u obzir razvoj modela osjetljivosti uzročnika na telitromicin i ostale antibiotike.
Rare cases of fainting (transient loss of consciousness), which may be preceded by a general feeling of being sick (e.g. nausea, stomach upsets) have been reported.
Prijavljeni su rijetki slučajevi nesvjestice (prolaznog gubitka svijesti), kojima može prethoditi opći osjećaj slabosti (npr. mučnina, nadražen želudac).
The patients should be carefully observed and given symptomatic and supportive treatment.
Bolesnike valja pažljivo nadzirati te poduzeti mjere simptomatskog i potpomog liječenja.
Concomitant administration of strong CYP3A4 inhibitors (such as telithromycin) and calcium channel blockers that are metabolized by CYP3A4 (e.g. verapamil, nifedipine, felodipine) may result in hypotension, bradycardia or loss of consciousness, and should therefore be avoided.
Istodobna primjena snažnih inhibitora CYP3A4 (poput telitromicina) i blokatora kalcijevih kanala koji se metaboliziraju putem CYP3A4 (npr. verapamil, nifedipin, felodipin) može izazvati hipotenziju, bradikardiju ili gubitak svijesti, pa je stoga treba izbjegavati.
Reports have included death and life threatening acute respiratory failure with rapid onset (see section 4.8).
Prijavljeni slučajevi uključivali su one sa smrtnim ishodom i po život opasnim akutnim zatajenjem disanja s naglim nastupom (vidjeti dio 4.8).
This could result in QT interval prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes.
To može rezultirati produljenjem QT-intervala i srčanim aritmijama, uključujući ventrikulamu tahikardiju, ventrikulamu fibrilaciju i torsades de pointes.
In addition, rare cases of transient loss of consciousness, which may be preceded by vagal symptoms, have been reported (see section 4.8).
Osim toga, prijavljeni su rijetki slučajevi prolaznog gubitka svijesti kojima mogu prethoditi simptomi vagusnog sindroma (vidjeti dio 4.8).
Due to its CYP3A4 inhibitory potential, telithromycin can increase blood concentrations of these CYP34A4 substrates.
S obzirom na inhibicijski potencijal prema CYP3A4, telitromicin može povećati koncentracije navedenih supstrata CYP3A4.
No dosage adjustment is necessary in patients with mild or moderate renal impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem bubrega.
Due to limited experience, Ketek should be used with caution in patients with liver impairment (see
Zbog ograničenog iskustva, Ketek treba primjenjivati uz oprez u bolesnika s narušenom funkcijom
In vivo studies with simvastatin, midazolam and cisapride have demonstrated a potent inhibition of intestinal CYP3A4 and a moderate inhibition of hepatic CYP3A4.
U ispitivanjima in vivo, simvastatin, midazolam i cisaprid su pokazali snažnu inhibiciju intestinalnog CYP3A4 te umjerenu inhibiciju jetrenog CYP3A4.
However, patients should be carefully monitored for signs and symptoms of myopathy and rhabdomyolysis when co-treated with pravastatin, rosuvastatin and fluvastatin.
Međutim, bolesnike trebaju biti pomno nadzirati kako bi se uočili znakovi i simptomi miopatije i rabdomiolize kada se istodobno liječe pravastatinom, rosuvastatinom i fluvastatinom.
Post-marketing cases of severe hepatitis and liver failure, including fatal cases (which have generally been associated with serious underlying diseases or concomitant medicinal products), have been reported (see section 4.8).
Nakon stavljanja lijeka u promet prijavljeni su slučajevi teškog hepatitisa i zatajenja jetre, uključujući i one sa smrtnim ishodom (koji su u pravilu bili povezani s ozbiljnim osnovnim bolestima ili istodobno primijenjenim lijekovima) (vidjeti dio 4.8).
Thus, when initiating telithromycin in patients already receiving any of theses immunosuppressive agents, cyclosporin, tacrolimus or sirolimus levels must be carefully monitored and their doses decreased as necessary.
Stoga se prilikom uvođenja telitromicina u bolesnika koji već primaju neki od ovih imunosupresivnih lijekova moraju pažljivo nadzirati koncentracije ciklosporina, takrolimusa odnosno sirolimusa te po potrebi smanjiti njihova doza.
Telithromycin is metabolised primarily by the liver.
Telitromicin se primarno metabolizira u jetri.
Light orange, oblong, biconvex tablet, imprinted with ‘H3647' on one side and ‘400' on the other.
Svijetlonarančasta, ovalna, bikonveksna tableta, s utisnutom oznakom 'H3647' na jednoj i '400' na